A Maintenance Study Evaluating the Long Term Safety of XL184 in Subjects With Advanced Malignancies Previously Enrolled in Other XL184 Studies

Trial Profile

A Maintenance Study Evaluating the Long Term Safety of XL184 in Subjects With Advanced Malignancies Previously Enrolled in Other XL184 Studies

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2013

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 28 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top